

Index

Entries for tables, figures, and boxes are noted in bold typeface.

- 2-component model for psychopathy, 324–327, **325**
- 5-HT brain receptors and impulsive violence, 148–149
- 5-HT1A brain receptor and mood disorders, 118
- 5-HT1B brain receptor and impulsive violence, 118 and serotonin, **146**
- 5-HT2A brain receptor and impulsive violence, 119 and serotonin, **146**
- 5-HT3 brain receptor and dopamine levels, 119–120
- acute hospital settings interventions, 42–44 risk assessment for violence, 42
- addictions. *See* substance abuse
- aggression and amygdala size, 107–109 and dopamine levels in the brain, 81–82, 120–121 and psychopathy, 271–272 and serotonin, 114–120 Cal-VAT etiology guidelines, 156–157 definitions of, **53** intermittent explosive disorder, 105–106 typology of, 27, 27–28, 104–105
- aggressive replacement therapy (ART), 286
- agitation and likelihood of future violence, 40, **41** Cal-Vat, 158–159, **160** medications, 43–44 psychopharmacological interventions, 213–216, **214** rating scales for, 212
- alcohol and 5-HT3 brain receptor, 119–120 and depression, 35 and violence risk, **36**
- altruistic filicide, 35
- amisulpride, 202–209, **204–205**
- amygdala and aggressive behaviors, 75, 77, 123 and prefrontal cortex, 110–113, **112** and psychopathy, 98 and schizophrenia, **139** structural and functional studies, 106–110, **107**, 292
- angry affect and likelihood of future violence, 41, 41 and violence, **33** in emotional interventions, 284, **285**
- anterior cingulate cortex (ACC) and aggression, 123–124 and amygdala responsivity, 110–113, **112**
- anti-impulsive aggressive agent (AIAA), 274–276
- antipsychotic drugs. *See also* medications and deinstitutionalization of severely mentally ill, 1 and impulsive violence, 75, 78 and psychotic violence, 74, 78 for treatment-resistant schizophrenia, 225–226 high plasma, 234–240, **236** not responsive in predatory violence, 76
- antisocial personality disorder (ASPD) and criminalness, 292–293, 324–325 and psychopathy, 269, 273–274 clozapine to treat, 187–198, **189**, **191–193** guidelines, 326
- anxiety and 5-HT1A brain receptor, 118 and likelihood of future violence, 41, **41**, **58** and psychopathy, 98
- AOT. *See* assisted outpatient treatment
- arginine vasopressin (AVP) system, 121–122
- aripiprazole for agitation, 214, 215 for treatment-resistant schizophrenia, 227, 228–229, 235
- asenapine for agitation, 214, 216 for treatment-resistant schizophrenia, 227, 229, 235
- ASPD. *See* antisocial personality disorder
- assisted outpatient treatment (AOT), 7
- attention deficit hyperactivity disorder (ADHD) and dopamine levels in the brain, 86 and tryptophan, 115 Cal-VAT, 160 stimulants to treat, 81
- auditory hallucinations. *See* hallucinations and violence risk
- Barratt Impulsiveness Scale (BIS), 136
- Behavioral Activity Rating Scale (BARS), 212
- behavioral management intervention for forensic patients, 307–308 to prevent violence in hospitals, 42–43
- binging, 91
- bipolar disorder and violence risk, 35, 56, 57–58 Cal-VAT, 160 numbers afflicted, 2
- body-worn video, **318–319**
- Bolam test, 254
- border personality disorder (BPD) and psychopathy, 272 clozapine to treat, 196–197 dopamine dysfunction and, 195 medications for, 187
- brain. *See also* neurobiology malfunction and violence, 73–78 prefrontal cortex and amygdala interactions, 110–113, **112** serotonin hypothesis, 145–151 striatum, 113–114
- Brief Psychiatric Rating Scale Cal-VAT. 158 for psychopathy, 216
- Broadmoor High Secure Hospital, 314, 318–320, **320**
- Brøset Violence Checklist (BVC) aggressive behaviors, 28, 212 risk assessment, 42, **43**
- Buddi GPS tracker, **316–317**

- building security
 - in classification of inpatient violence, 12
 - in dimensional conceptualization of inpatient violence, 12
- Bureau of Labor Statistics, 24
- Buss-Perry Aggression Questionnaire (BPAQ), 105, 158
- Cal-VAT. *See* California State Hospital Violence Assessment and Treatment Guidelines
- California Department of State Hospitals (DSH)
 - ecological interventions, 263–267, 266–267
 - inpatient violence, 49–50
 - principles for treatment, 234–235
- California State Hospital Violence Assessment and Treatment Guidelines (Cal-VAT)
 - assessment, 156–157
 - background, 155–156
 - case studies, 243–250
 - impulsive violence, 160–162
 - predatory violence, 162–164
 - psychopharmacological interventions, 158–159
 - psychosocial interventions, 164–167
 - psychotic violence, 159–160
 - setting and housing, 167–169
 - violence risk assessment, 157–158
- callous-unemotional (CU) traits, 110
- case studies
 - for treatment-resistant schizophrenia, 238–240
 - impulsive violence, 245–249
 - inpatient violence, 193, 193–195
 - predatory violence, 246–249
 - psychotic violence, 243–245, 249–250
 - schizophrenia, 203–206
 - to support Cal-VAT guidelines, 243–250
- CATIE. *See* Clinical Antipsychotic Trials of Intervention Effectiveness
- chlorpromazine, 1
- classification
 - of aggression, 27, 27–28
 - of psychiatric violence, 12, 12
- Classification of Violence Risk (COVR), 12, 18, 21, 26, 158
- Clearwater Sex Offender Programme, 326
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 177–183, 180, 182
- clinical assessment
 - and psychiatrist duty to protect, 65, 65–66
 - and TPR, 280–283
- Cal-VAT etiology guidelines, 156
- importance of documentation in, 67–69
- of psychiatric violence, 32–36, 40–41, 41
- of psychopathy, 323–324
- serotonin and impulsive aggression, 147, 150–151
- Clinical Global Impression (CGI) scale
 - and clozapine, 188–190
 - for combination clozapine and amisulpride, 203
- closed circuit television (CCTV), 317–319, 318
- clozapine
 - for ASPD, 187–198
 - for psychopathy, 216–217
 - for psychotic violence, 244–245, 248–249
 - for schizophrenia, 202–209, 204
 - for treatment-resistant schizophrenia, 226–227, 227, 235–236, 249–250
- cognitive behavioral therapy
 - and impulsive violence, 93
 - in TPR, 283, 284
- cognitive impairment
 - Cal-VAT psychosocial intervention, 167
 - self-empowerment of, 283–284
- Cohen–Mansfield Agitation Inventory (CMAI), 158
- command hallucinations, 33–34
- community hospital. *See* mental hospitals
- community treatment disorders. *See* assisted outpatient treatment
- computed tomography (CT), 82–83, 83
- conditional release for mental illness, 7–8
- correctional setting. *See also* mental hospitals
 - and treatment of mentally ill, 10–11, 294–296
 - violence risk assessment, 20–21
 - violent inpatient treatment, 12–14
- cortisol, 122–124
- court order
 - and committing forensic patients to a state hospital, 49–50, 52
 - and inpatient aggression, 56, 60
 - and treatment of mentally ill, 7–8, 252–255, 253
 - for psychiatrists to protect, 64–71
 - interventions, 305–306
- criminalness. *See also* forensic patients, recidivism
 - and impulsive violence, 90–91, 325, 327
 - and mental health courts, 8
 - and psychopathy, 270–271
 - and schizophrenia, 203–206, 327–328
- Cal-VAT, 165
- clozapine to treat, 187–198, 189, 191, 193
- housing, 293–296, 294
- relationship with mental illness, 291–293, 291, 303–304
- sequential intercept mapping workshops for, 304, 305
- treatment, 296–298
- Crisis Intervention Team (CIT), 304–305
- Critical Time Intervention, 306
- CT. *See* computed tomography
- culture of care, 281–283
- culture of incarceration, 309
- data practices with inpatient violence, 12, 12, 19–20, 21, 67–69
- deinstitutionalization of severely mentally ill, 2–7
- delusions
 - and schizophrenia, 140
 - and violence risk, 32–33, 32–33
- demographics
 - and inpatient aggression, 52, 54–56, 55, 60
 - of forensic patients by legal class, 52
- Department of Justice National Crime Victimization Survey for 1993 through 1999, 24
- depression
 - and violence risk, 34–35, 56, 57–58
- Cal-VAT, 160
- technology to monitor, 314
- Diagnostic and Statistical Manual of Mental Disorders* (DSM), 51, 73, 151, 188, 269
- dialectical behavioral therapy (DBT)
 - and psychotic and impulsive violence, 78
 - for impulsive violence, 93, 247–248, 307
- documentation. *See* data practices with inpatient violence
- dopamine overactivity
 - and 5-HT₃ brain receptor, 119–120
 - and aggression, 81–82, 120–121, 195
 - and psychotic violence, 74
 - and striatum, 113
 - psychopharmacological interventions, 221–222, 223
 - role of in violence, 76–77, 92
 - with TBI, 81–87

Index

- drug abuse
 and impulsivity–compulsivity behavior, 90
 as confounding factor for treatment, 76
 drug court, 305
 duty to protect, 64–71
 Dynamic Appraisal of Situational Aggression (DASA)
 and risk assessment, 28, 42, 43
 Cal-VAT guidelines, 158
- ecological systems theory, 263
 electronic monitoring of patients, 315–317
 emotional interventions, 284–285, 285
 and likelihood of future violence, 41–42
 Cal-VAT etiology guidelines, 156–157
 ecological systems theory, 263–267, 266–267
 environmental interventions, 44
 Epidemiological Catchment Area (ECA) surveys, 3–4, 33
 ethnicity and aggression, 51–52, 54–55, 55, 60
 European First-Episode Schizophrenia Trial (EUFEST), 177, 181–183
- factors behind deinstitutionalization of mentally ill, 2–7
 factors for criminal behavior, 292–293
 factors for description for psychopathy, 96, 100
 factors for likelihood of inpatient violence, 40–42, 69–70
 factors for schizophrenia, 136
 families of mentally ill, 4
 fear in interventions, 285, 285
 filicide, 34
 fluoro-deoxyglucose positron emission tomography (FDG-PET), 109
 fluphenazine, 235–236, 236, 238–239
 focal brain lesions
 and dopamine levels in the brain, 81–82, 84–87
 CT scans for focal brain lesions, 82–83, 83
 Forensic Assertive Community Treatment, 306
 forensic patients. *See also* criminalness
 ecological interventions, 263–267, 266–267
 in mental hospitals, 10–14
 intervention guidelines, 252–255, 253, 258–261, 259
 legal classes of, 52
- Gage, Phineas, 96, 97
 gender and aggression, 52, 54, 54–55, 59
 genetic analysis
 and dopamine levels in the brain, 120–121
 and psychopathy, 98
 for aggression, 83
 MAOA, 117–118
 of serotonin, 116
 of vasopressin, 121–122
 global positioning systems (GPS), 315–317, 316–317
 guidelines
 ASPD, 326
 Cal-VAT, 155–169
 for forensic patient interventions, 252–255, 253, 258–261, 260
 for treatment-resistant schizophrenia, 223–225
- habit
 as stimulus-response learning system, 90–92
 treatment for impulsive violence as, 92–94
- hallucinations and violence risk, 33–34
 haloperidol
 for agitation, 214
 for treatment-resistant schizophrenia, 235–236, 236, 239
 Hare Psychopathy Checklist (PCL-R), 12, 24–27, 26, 158, 188, 192, 195, 269, 271–272, 323–324
 high plasma level antipsychotics, 234–240, 236
- Historical, Clinical, Risk Management-20 (HCR-20)
 and community, 25–27, 26
 and risk assessment, 12, 18, 21, 42
 Cal-VAT, 158
- homicides
 and psychopathy, 96
 and schizophrenia, 4
 and severe mental illness, 6, 6–7
- hospital staff. *See also* mental health professionals
 and likelihood of future violence, 41
 Cal-VAT etiology guidelines, 157
 psychiatrists duty to protect, 64–71
 reporting violent situations, 39–40, 40, 50
- hostility
 CATIE definition, 177–178, 183
 scales for, 212
- housing. *See* mental hospitals
- iloperidone, 227, 229
 imminent aggression, 27
- impulsive violence
 and 5-HT1B brain receptor, 118
 and 5-HT2A brain receptor, 119
 and compulsive behaviors, 90
 and psychopathy, 271–272, 274–276
 and serotonin, 145–151, 146
 and striatum, 113–114
 areas of the brain affected, 74–75, 74–75, 77
 as syndrome of violence, 73–74, 74, 216
 as the inability to resist urges, 90–91
 Cal-VAT guidelines, 156, 160–162, 166–167
 case studies, 245–249
 interventions, 78, 92–94, 221–229
 maladaptations in brain circuitry, 91–92, 92
 prefrontal cortex rewards for, 92–93
 schizophrenic, 136–141
 incompetence to stand trial, 260
 independent forensic evaluation
 and forensic interventions, 252–255, 253
 in dimensional conceptualization of inpatient violence, 10, 12, 12
- inpatient violence
 and impulsivity, 136
 case studies, 192, 193–195
 definitions of aggression, 53
 in community hospitals, 39–45
 motivators of, 11, 11
 psychopharmacological interventions for, 212–218
 risk assessment, 24–29
 treatment, 12–14
- institutional aggression, 25–28
 instrumental aggression, 145, 216
 intermittent explosive disorder
 and aggression, 105–106
 and psychopathy, 273–274
 being common, 145
 Cal-VAT, 160
- interventions. *See also* treatment
 community re-entry, 306
 ecological, 263–267, 266–267
 for forensic inpatients, 252–255, 258–261, 259
 for psychopathy, 269–276, 323–328
 in dimensional conceptualization of inpatient violence, 29
 police-based, 304–305
 psychosocial, 279–287
 technology to monitor, 314–320
 to prevent violence in hospitals, 39, 42–44
 involuntary treatment option for mental illness
 AOT, 7

- conditional release, 7–8
court-ordered, 305–306
mental health courts, 8
- Kendra's Law, 7
- Laura's Law, 7
- legal classes
and inpatient aggression, 60
of forensic patients, 52
- legal commitment. *See* court order
- legal context
and deinstitutionalization of severely mentally ill, 1
violence risk assessment, 17
- legal error, 69
- length of stay and patient aggression, 59
- lithium, 248–249
- lorazepam, 214
- loxapine, 214, 215
- lurasidone, 227, 229, 235
- MacArthur Study of Mental Disorder and Violence, 33
- MacArthur Violence Risk Assessment Study, 35
- MacArthur–Maudsley Delusions Assessment Schedule, 33
- magnetic resonance imaging (MRI)
and amygdala responsivity, 109–110, 292, 299
and serotonin, 113–114
of schizophrenia, 139–140
- mania. *See* bipolar disorder
- MAOA. *See* monoamine oxidase A
- mass killings. *See* homicides
- McNeil–Binder Violence Screening Checklist (VSC), 28, 42, 43
- medications. *See also* antipsychotic drugs, psychopharmacological interventions
and violence, 4, 7
Cal-VAT etiology guidelines, 156
failure of, 222–223, 224
to treat aggression, 81–82
- Medium Secure Service, 316–317, 316–317. *See also* mental hospitals
- Mendota Juvenile Treatment Center (MJTC), 285
- mental health professionals. *See also* hospital staff
and risk for violence, 24, 264
TPR training, 281–282
- mental hospitals. *See also* Medium Secure Service, correctional setting and forensic interventions,
252–255, 258–261, 253, 293–296, 294
- and inpatient aggression, 11–13, 39–45, 49–62
as factor in deinstitutionalization, 1
Cal-VAT guidelines, 157, 167–169
conditional release, 7–8
incarceration and lack of violence, 1, 5
length of stay and aggression, 59
predatory violence exceeding security, 246–247
violence increase in, 10–14
- mental illness
and criminalness, 291–293, 291, 303–304
and homicides, 6, 6–7
involuntary treatment option, 7–8
recidivism, 303–304
- mirtazapine, 247–248
- MISSION-Criminal Justice, 308–309
- monoamine oxidase A (MAOA), 117–118
- mood disorders. *See also* psychosis
and 5-HT1A brain receptor, 118
and violence risk, 34–35
Cal-VAT guidelines, 161
technology to monitor, 314
- Moral Reconnection Therapy, 308
- motion detector technology, 319–320, 320
- murder. *See* homicides
- narcissism, 99, 100
- National Alliance for the Mentally Ill (NAMI), 4
- National Institute of Mental Health (NIMH), 2
- neurobiology. *See also* brain
after penetrating brain injury, 81–87
and dopamine levels in the brain, 120–121
and impulsive violence addiction, 90–94
and medication failure, 222–223, 224
and serotonin, 114–120
of psychopathy, 96–101, 272–273
of schizophrenic impulsive violence, 136–141, 139, 234
of violence, 104–114, 291–292
- Neuropsychiatric Inventory (NPI-a), 82
- neurotransmitters (brain)
and schizophrenia, 136–141
and serotonin, 147
and violence, 76–77, 114–125
- New Hampshire State Hospital, 7
- New York Times* (newspaper), 4–5
- Occupational Safety and Health Administration (OSHA), 24
- olanzapine
CATIE study, 183
for agitation, 213, 214
for psychopathy, 217
for psychotic violence, 243–244
for treatment-resistant schizophrenia, 227, 228, 235, 236, 236, 239–240
- orbitofrontal cortex (OFC)
and aggression, 123–124
and amygdala responsivity, 110–113, 112
response to negative pictures, 137
- Overt Aggression Scale (OAS), 212
- paliperidone, 227, 235
- patient–patient factors to violence, 40–41, 41
- peer support and recovery, 310
- persecutory delusions. *See* delusions
- persistent aggressive behavior. *See* psychopathy
- pharmacology. *See* psychopharmacological interventions
- Point Subtraction Aggression Paradigm (PSAP), 109, 137, 141
- police-based interventions, 304–305
- Positive and Negative Syndrome Scale (PANSS), 177–179, 181–183, 212
- positron emission tomography (PET)
and 5-HT2A brain receptor, 119
and brain receptors, 125
and dopamine levels in the brain, 120–121
and schizophrenia, 138
- post-traumatic stress disorder
and TPR, 309
Cal-VAT guidelines, 160
- predatory violence
and hypoactive amygdala, 75
areas of the brain affected, 75
as syndrome of violence, 73–74, 74
Cal-VAT guidelines, 156, 162–164, 165, 166–167
case studies, 246–249
- prefrontal cortex
and amygdala interactions, 110–113, 112
and focal brain lesions, 81–82
and impulsive–compulsive behavior, 92–93
and psychopathy, 98–99, 99–100
and striatum, 113–114
- proactive aggression
and amygdala responsivity, 110
components of, 105
- psychiatric setting. *See* mental hospitals

Index

- Psychopathic Personality Inventory, 120
- psychopathy
 and areas of the brain, 96–101, 97, 99–100
 and childhood adversity, 97
 clozapine to treat, 197
 genetic analysis for, 98
 interventions for, 269–276, 323–328
 medications for, 100
 psychopharmacological interventions, 216–218
- Psychopathy Checklist. *See* Hare Psychopathy Checklist
- psychopharmacological interventions. *See also* medications
 and serotonin, 114–120
 clozapine, 187–198
 for psychopathy, 100, 273–276
 for schizophrenia, 177–183, 180–181
 for treatment-resistant schizophrenia, 202–209, 204, 221–229, 234–240
 reducing impulsive violence, 73
 to prevent violence in hospitals, 43–44, 212–218
 to support Cal-VAT guidelines, 158–164, 160–162, 243–250
- psychosis, 32–33, 32–34, 56, 57, 327.
See also mood disorders
- psychosocial interventions
 Cal-VAT guidelines, 163, 164–167, 165
 contextually anchored, 279–287
- psychotic violence
 areas of the brain affected, 74, 75
 as syndrome of violence, 73–74, 74
 Cal-VAT guidelines, 156, 159–160, 159–160, 161, 165, 166
 case studies, 243–245, 249–250
 interventions, 78, 221–222, 222
- PubMed database, 39
- quetiapine, 227, 228, 235
- RAGE-Control intervention, 286
- reactive violence. *See* impulsive violence
- reason for rise in violence
 and forensic mental health systems, 10–14
 deinstitutionalization of severely mentally ill, 7–8
- recidivism. *See also* criminalness
 2-component model for
 psychopathy, 325–327
 and mental illness, 303–304
 and violence risk reduction, 307–309
 peer support to prevent, 310
- Recovery Inspired Skills Enhancement (RISE), 167
- Research Domain Criteria (RDoC)
 and schizophrenia, 137
 in psychopathology, 73–74, 74, 77
 responsivity principle, 165
- risk assessment. *See also* violence risk assessment
 for inpatient violence, 42, 43
 importance of documentation in, 67–69
 of psychiatrists duty to protect, 69–71
 of psychosis and mood disorders, 35–36, 36
 of violence with clozapine, 192–193
- Risk-Need-Responsivity Model
 and criminalness, 297, 299, 306–307, 307, 326
 Cal-VAT, 164
- risperidone, 227, 228, 235–236, 236
- safety
 and behavioral interventions, 42–43
 and collaborative forensic treatment, 306
 and treatment of mentally ill, 10–11
 and violent inpatient treatment, 12–14, 246–247
 psychiatrists duty to protect, 64–71
- schizoaffective disorder, 56, 57–58
- schizophrenia
 and homicides in 1980s, 3
 and homicides, 4
 and impulsive violence, 136–141, 139
 and substance abuse, 6, 76
 and TCO, 33
 and violence, 4, 34, 56, 57–58, 327–328
 Cal-VAT guidelines, 159
 numbers afflicted, 2
 psychopharmacological interventions, 177–183, 180–181, 221–229, 234–240
- secure continuous remote alcohol monitoring (SCRAM), 315
- selective serotonin reuptake inhibitor (SSRI)
 and cortisol levels, 122
 and psychopathy, 273
 and serotonin, 115, 149–150, 150
- Sensitizing Providers to the Effects of Correctional Incarceration on Treatment and Risk Management (SPECTRM), 309
- sequential intercept mapping model, 304, 305
- serotonin
 and aggression, 114–120, 124, 145–151, 146, 196
 and amygdala responsivity, 113
 and psychopathy, 273
 and striatum, 113–114
 imbalances of, 76–77
- serotonin transporter genes, 116–117
- severe mental illness
 and homicides, 2–3, 6–7, 6
 and violent behavior, 4–7, 5
 rate of, 2
 treatment percentages, 2
- Sex Offender Risk Appraisal Guide (SORAG), 42
- shame in interventions, 285
- Short Term Assessment of Risk and Treatability (START), 12, 158
- single nucleotide polymorphism, in dopamine system (SNP)
 and dopamine levels in the brain, 84–87
 and tryptophan hydroxylase-2, 116
 with TBI, 81–82, 84
- Social Security Disability Insurance (SSDI), 1
- SSRI. *See* selective serotonin reuptake inhibitor
- staff. *See* mental health professionals
- Staff Observation Aggression Scale (SOAS), 158
- steroid hormones, 122–124
- striatum
 and aggression, 124
 and schizophrenia, 139
- structural professional judgment of
 violence risk assessment, 18, 25, 28
- structured clinical instruments, 42
- substance abuse
 and mental illness, 303
 and psychopathy, 274
 and schizophrenia, 6
 in dimensional conceptualization of inpatient violence, 12, 12, 308–309
 peer support, 310
 psychopharmacological interventions, 213
- Substance Abuse and Mental Health Services Administration (SAMHSA), 309–310
- suicide
 and homicides, 34–35, 36
 and serotonin, 145–147
 technology to prevent, 314
- Supplemental Security Income (SSI), 1
- Tarasoff (legal decision), 64–65
- Taylor Aggression Paradigm (TAP), 137, 141

- TBI. *See* traumatic brain injury
 TCO. *See* threat control-override symptoms
 technology in interventions, 314–320
 testosterone, 122–124
The International Handbook of Psychopathic Disorders and the Law, 272
 threat
 in Tarasoff situations, 66–67, 67
 perception in impulsive and psychotic violence, 74–75, 77
 threat control-override symptoms (TCO), 32–33, 36
 TPR. *See* trauma-informed recovery
 transcranial magnetic stimulation (TMS), 140–141
 trauma-informed recovery (TPR).
 See also traumatic brain injury and violence risk, 283–286, 284–285
 clinical assessment, 280–283
 mission of, 279–280, 280, 309–310
 perspective, 279–280
 traumatic brain injury (TBI). *See also*
 trauma-informed recovery and dopamine levels in the brain, 81–82
 Cal-VAT guidelines, 160
 CT scans for focal brain lesions, 82–83
 treatment. *See also* interventions and safety, 10–11
 and violent behavior among mentally ill, 7–8
 for criminalness, 296–298
 in dimensional conceptualization of inpatient violence, 12–13, 12–13
 of schizophrenia, 139–140
 serotonin and impulsive aggression, 149–150, 150
 trifluoperazine, 238
 tryptophan
 and aggression, 114–115
 and serotonin, 146
 tryptophan hydroxylase-2, 116
 typology. *See* classification
 untreated mental illness, 3–5, 5
 valproate, 235
 vasopressin, 121–122
 violence
 as a medical syndrome, 10, 73–78, 90
 as process in TPR, 280
 prevalence in mental hospital setting, 40, 40, 49–62
 psychopharmacological interventions for, 212–218
 reduction in forensic institutions, 263–267, 266–267
 violence increase
 and untreated mental illness, 3–5
 in mental hospitals, 10–14
 to families of mentally ill, 4
 Violence Prediction Scheme (VPS), 42
 violence prevention
 community programs, 306–310
 TPR, 285–286
 Violence Reduction Program, 326
 Violence Risk Appraisal Guide (VRAG), 18, 21, 25–27, 26, 42, 158
 violence risk assessment. *See also* risk assessment
 2-component model for psychopathy, 325, 325–327
 and recidivism, 307–309
 Cal-VAT guidelines, 157–158
 development of, 24–27, 26
 evolution of, 17–22, 18
 for forensic patient interventions, 258–259, 259
 in dimensional conceptualization of inpatient violence, 12–14, 12–13
 of aggression, 24–29
 TPR, 283–285, 284–285
 Violence Risk Scale (VRS), 158, 325–327, 325
 Violence Risk Screening-10 (V-RISK-10), 12, 158
 ziprasidone
 for agitation, 213, 214
 for treatment-resistant schizophrenia, 227, 228, 235